4D Molecular director David Kirn sells 58K shares

Q: At what prices were David Kirn’s FDMT shares sold?

The Form 4 shows weighted average sale prices of $12.8656 for 42,608 shares on July 9, $12.8355 for 442 shares on July 10, and $12.0107 for 15,283 shares on July 10, with trades executed within stated intraday price ranges.

Q: How many FDMT shares does David Kirn own after these sales?

After the reported transactions, David Kirn directly owns 884,152 shares of 4D Molecular Therapeutics common stock. Each transaction entry lists post-trade holdings, and the final July 10, 2026 sale shows this direct ownership balance remaining.

Q: Did the FDMT Form 4 include any option exercises or derivative trades?

No. The filing’s transaction data show only non-derivative common stock sales, with no option exercises and no derivative transactions reported. The derivative transaction count and exercise share totals are both listed as zero.

Accepted by SEC EDGAR 07/14/2026 - 05:04 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. director and officer David Kirn reported three open-market sales totaling 58,333 shares of common stock on July 9–10, 2026, at weighted average prices of $12.8656, $12.8355 and $12.0107 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 884,152 shares of FDMT common stock.

Insider Trade Summary 10b5-1

Net Seller: 58,333 shares

Net Sell 3 txns

Insider Kirn David

Role See Remarks

Sold 58,333 shs ($737K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F3}	15,283	$12.0107	$184K
Sale	Common Stock ^{F1, F4}	442	$12.8355	$6K
Sale	Common Stock ^{F1, F2}	42,608	$12.8656	$548K

Holdings After Transaction: Common Stock — 884,152 shares (Direct)

Footnotes (4)

F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
F2. The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4. The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Total shares sold: 58333 shares Sale price for 42,608-share trade: $12.8656 per share Sale price for 442-share trade: $12.8355 per share +3 more

6 metrics

Total shares sold 58333 shares Aggregate open-market sales of common stock on July 9–10, 2026

Sale price for 42,608-share trade $12.8656 per share Weighted average sale price for 42,608 shares sold on July 9, 2026

Sale price for 442-share trade $12.8355 per share Weighted average sale price for 442 shares sold on July 10, 2026

Sale price for 15,283-share trade $12.0107 per share Weighted average sale price for 15,283 shares sold on July 10, 2026

Shares held after transactions 884152 shares Direct FDMT common stock holdings by David Kirn after the July 10, 2026 sale

10b5-1 plan adoption date January 9, 2026 Date the Rule 10b5-1 trading plan governing these sales was adopted

Key Terms

10b5-1 trading plan, weighted average sale price, open-market sale

3 terms

10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

open-market sale financial

"Transaction code S described as a Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock sales in FDMT did David Kirn report?

4D Molecular Therapeutics officer and director David Kirn reported selling 58,333 shares of FDMT common stock in three open-market sales on July 9–10, 2026, executed under a Rule 10b5-1 trading plan at weighted average prices around $12 per share.

At what prices were David Kirn’s FDMT shares sold?

The Form 4 shows weighted average sale prices of $12.8656 for 42,608 shares on July 9, $12.8355 for 442 shares on July 10, and $12.0107 for 15,283 shares on July 10, with trades executed within stated intraday price ranges.

How many FDMT shares does David Kirn own after these sales?

After the reported transactions, David Kirn directly owns 884,152 shares of 4D Molecular Therapeutics common stock. Each transaction entry lists post-trade holdings, and the final July 10, 2026 sale shows this direct ownership balance remaining.

Were David Kirn’s FDMT stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a 10b5-1 trading plan adopted by David Kirn on January 9, 2026, indicating the sales were pre-arranged rather than discretionary market-timed trades.

Did the FDMT Form 4 include any option exercises or derivative trades?

No. The filing’s transaction data show only non-derivative common stock sales, with no option exercises and no derivative transactions reported. The derivative transaction count and exercise share totals are both listed as zero.

How many FDMT shares in total did David Kirn sell in this Form 4?

Across the three open-market transactions, David Kirn sold an aggregate of 58,333 shares of 4D Molecular Therapeutics common stock, according to the Form 4 transaction summary, which classifies the overall activity as a net sell of that share amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last)

(First)

(Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE

CALIFORNIA

94608

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/09/2026		S⁽¹⁾		42,608	D	$12.8656⁽²⁾	899,877	D
Common Stock	07/10/2026		S⁽¹⁾		15,283	D	$12.0107⁽³⁾	884,594	D
Common Stock	07/10/2026		S⁽¹⁾		442	D	$12.8355⁽⁴⁾	884,152	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

2. The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President and Chief Executive Officer

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR